Otonomy to Host Virtual Investor R&D Event on March 22, 2022
February 25 2022 - 7:30AM
Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced that it will host a virtual Investor
R&D Event from 10 a.m. - Noon ET on March 22, 2022.
This event will include presentations by key opinion leaders who
will provide background information on tinnitus and hearing loss
and review the positive Phase 1/2 trial results for Otonomy’s
OTO-313 and OTO-413 product candidates that target these
conditions. Additionally, members of Otonomy’s senior management
team will provide an update on ongoing clinical trials and outline
next steps for these programs.
External speakers participating in this event include:
- Barbara Shinn-Cunningham, Ph.D., Director, Carnegie Mellon
Neuroscience Institute and Cowan Professor of Auditory
Neuroscience, Biomedical Engineering, Psychology, and Electrical
& Computer Engineering at Carnegie Mellon University
- Victoria Sanchez, Au.D., Ph.D., Research Assistant Professor in
Department of Communication Sciences and Disorders at University of
South Florida
- David Baguley, Ph.D., Professor of Hearing Sciences at the
University of Nottingham, former Head of Audiology at Cambridge
University Hospitals NHS Foundation Trust
- Anthony Mikulec, M.D., Chief of Otologic and Neurologic Surgery
and Professor in the Department of Otolaryngology – Head and Neck
Surgery at Saint Louis University School of Medicine
To register for Otonomy’s Virtual Investor R&D Event, please
sign up here. Registration for this event and access to the webcast
will be available on the investor relations section of Otonomy’s
website at Events | Otonomy Inc. An archived replay of the webcast
will be available from the Otonomy website at Events | Otonomy
Inc.
About OtonomyOtonomy is a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology. The company pioneered the application of drug delivery
technology to the ear in order to develop products that achieve
sustained drug exposure from a single local administration. This
approach is covered by a broad patent estate and is being utilized
to develop a pipeline of products addressing important unmet
medical needs with a focus on hearing loss and tinnitus. For
additional information please visit www.otonomy.com.
Contacts:
Media InquiriesSpectrum ScienceCate CullenAccount
Director205.910.4443ccullen@spectrumscience.com
Investor InquiriesICR WestwickeRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From May 2024 to Jun 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2023 to Jun 2024